L
Lai Wang
Publications - 9
Citations - 456
Lai Wang is an academic researcher. The author has contributed to research in topics: Ibrutinib & Neutropenia. The author has an hindex of 7, co-authored 9 publications receiving 307 citations.
Papers
More filters
Journal ArticleDOI
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL
Constantine S. Tam,Judith Trotman,Judith Trotman,Stephen Opat,Jan A. Burger,Gavin Cull,Gavin Cull,David Gottlieb,David Gottlieb,Rosemary Harrup,Rosemary Harrup,Patrick B. Johnston,Paula Marlton,Paula Marlton,Javier Munoz,John F. Seymour,D. Simpson,Alessandra Tedeschi,Rebecca Elstrom,Yiling Yu,Zhiyu Tang,Lynn Han,Jane Huang,William Novotny,Lai Wang,Andrew W. Roberts +25 more
TL;DR: Zanubrutinib demonstrated encouraging activity in CLL/SLL patients, with a low incidence of major toxicities, and definition of the maximum tolerated dose (part 1).
Journal ArticleDOI
The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/ Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human Trial
Constantine S. Tam,Constantine S. Tam,Andrew Grigg,Stephen Opat,Matthew Ku,Michael Gilbertson,Mary Ann Anderson,Mary Ann Anderson,Mary Ann Anderson,John F. Seymour,John F. Seymour,David Ritchie,Carmen Dicorleto,Belinda Dimovski,Eric Hedrick,Jianxin Yang,Lai Wang,Lusong Luo,Ling Xue,Andrew W. Roberts,Andrew W. Roberts,Andrew W. Roberts +21 more
TL;DR: The initial results of an ongoing phase 1 trial of BGB-3111 in patients (pts) with advanced B cell malignancies are reported, with no drug-related SAEs, AEs leading to drug discontinuation, or AE-related deaths.
Journal ArticleDOI
Twice Daily Dosing with the Highly Specific BTK Inhibitor, Bgb-3111, Achieves Complete and Continuous BTK Occupancy in Lymph Nodes, and Is Associated with Durable Responses in Patients (pts) with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Constantine S. Tam,Constantine S. Tam,Constantine S. Tam,Stephen Opat,Gavin Cull,Judith Trotman,Judith Trotman,David Gottlieb,David Gottlieb,David Simpson,Paula Marlton,Mary Ann Anderson,Matthew Ku,David Ritchie,David Ritchie,Sumita Ratnasingam,Bradley Augustson,Mark Kirschbaum,Lai Wang,Ling Xue,Jianxin Yang,Eric Hedrick,John F. Seymour,John F. Seymour,Andrew W. Roberts +24 more
TL;DR: The results of BTK occupancy analyses in LN specimens from a dedicated pharmacodynamics (PD) cohort are reported and safety and efficacy in patients with CLL/SLL are updated.
Journal ArticleDOI
Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK-cell effector function in patients with mantle cell lymphoma.
Thijs W. H. Flinsenberg,Charnelle C. Tromedjo,Nan Hu,Ye Liu,Yin Guo,Kevin Y. T. Thia,Tahereh Noori,Xiaomin Song,Han Xian Aw Yeang,Daniela Gm Tantalo,Sasanka M. Handunnetti,John F. Seymour,Andrew W. Roberts,David Ritchie,Rachel Koldej,Paul J Neeson,Lai Wang,Joseph A. Trapani,Constantine S. Tam,Ilia Voskoboinik +19 more
TL;DR: Compared peripheral NK-cell repertoire and function in the same patients before and after one month of monotherapy with ibrutinib or zanubrut inib, it was found that the repertoire of NKcell ligands on B cells of MCL patients was essentially unchanged.
Journal ArticleDOI
Efficacy of Zanubrutinib in the Treatment of Bing-Neel Syndrome.
Jonathan Wong,Lawrence Cher,James Griffiths,Aileen Cohen,Jane Huang,Lai Wang,Gareth P. Gregory,Stephen Opat +7 more
TL;DR: A 75-year-old female with Bing–Neel syndrome who responded to zanubrutinib, a second-generation Bruton tyrosine kinase (BTK) inhibitor, achieves a substantial reduction in the paraprotein to 4g/L and normalization of the hemoglobin, consistent with a partial response to rituximab.